Member of the Legislative Council Natasha Maclaren-Jones today welcomed the NSW Government’s announcement that a Memorandum of Understanding (MOU) has been signed with GW Pharmaceuticals (GW) to progress a major new research program for cannabis-based medicines in children with severe, drug resistant paediatric epilepsy.
Mrs Maclaren-Jones said many children are suffering and this announcement provides hope for families.
“This is a Government showing incredible progress, NSW is the first state in Australia to provide legal and safe access to cannabis-based medicines for children suffering from drug resistant epilepsy,” Mrs Maclaren-Jones said.
The MOU will facilitate:
- A world first, phase 2 clinical trial in children for GW’s novel product containing the cannabinoid cannibidivarin (CBDV)
- A compassionate access scheme for EpidiolexÒ, GW’s product containing cannabidiol (CBD) which is currently in late stage trials in paediatric epilepsy in the United States
- Provision for NSW to host additional Phase 3 clinical trials of EpidiolexÒ in children with treatment-resistant epilepsy
- A phase 4 clinical trial of EpidiolexÒ based on phase 3 studies
The MOU, between the NSW Government and GW Pharmaceuticals, comes as part of the NSW Government’s $21 million commitment to support clinical trials and establish the NSW Centre for Medicinal Cannabis Research and Innovation.
More information about medicinal cannabis in NSW is available at www.health.nsw.gov.au/cannabis.
Specific information regarding trials email firstname.lastname@example.org or call the Cannabis Trials Help Line on 1800 217 257.